#1 Clinical Trials Search in Europe

Mycophenolic Acid

Mycophenolic acid is an immunosuppressant drug that has been the subject of several clinical trials exploring its use in organ transplantation and autoimmune conditions. This article summarizes key findings from recent studies investigating mycophenolic acid’s efficacy, safety profile, and potential applications across different patient populations and treatment protocols.

Table of Contents

What is Mycophenolic Acid?

Mycophenolic acid is an immunosuppressant medication used primarily in organ transplant patients to prevent rejection. It’s also known by several other names, including mycophenolate sodium, mycophenolate mofetil, Myfortic, and Cellcept[1][2]. This drug works by suppressing your immune system to prevent it from attacking the transplanted organ.

Conditions Treated

Mycophenolic acid is used to treat several conditions:

  • Kidney transplantation: It’s commonly used to prevent rejection in kidney transplant recipients[3].
  • Heart transplantation: Some studies have explored its use in heart transplant patients[4].
  • Lupus nephritis: This is a type of kidney inflammation caused by lupus. Mycophenolic acid has shown promise in treating this condition[5].
  • Autoimmune uveitis: This is an inflammation of the eye that can be treated with mycophenolic acid in some cases[6].

How It Works

Mycophenolic acid works by inhibiting an enzyme called inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for the production of guanosine nucleotides, which are essential for the growth of T and B lymphocytes (types of white blood cells). By blocking this enzyme, mycophenolic acid prevents these immune cells from multiplying, thus suppressing the immune response[1].

Forms and Dosage

Mycophenolic acid comes in two main forms:

  • Mycophenolate mofetil (Cellcept): This is the original form of the drug.
  • Enteric-coated mycophenolate sodium (Myfortic): This is a newer formulation designed to reduce gastrointestinal side effects[4].

The typical dosage for kidney transplant patients is 720 mg twice daily for Myfortic, or 1000 mg twice daily for Cellcept[3]. However, dosages may vary depending on the specific condition being treated and individual patient factors.

Effectiveness

Mycophenolic acid has been shown to be effective in preventing organ rejection in transplant patients. In kidney transplant recipients, it can help reduce the risk of acute rejection episodes[1]. For lupus nephritis, studies have shown that it can induce remission in a significant number of patients[5].

Side Effects

Like all medications, mycophenolic acid can cause side effects. Some of the most common include:

  • Gastrointestinal issues: These can include diarrhea, nausea, and stomach pain. The enteric-coated form (Myfortic) was developed to help reduce these side effects[4].
  • Increased risk of infections: Because it suppresses the immune system, mycophenolic acid can make you more susceptible to infections[7].
  • Blood disorders: It may cause anemia (low red blood cells), leukopenia (low white blood cells), or thrombocytopenia (low platelets)[7].

Special Considerations

There are several important things to keep in mind when taking mycophenolic acid:

  • Food interactions: Some studies have looked at how food affects the absorption of mycophenolic acid. It’s important to take it consistently either with or without food as directed by your doctor[2].
  • Pregnancy: Mycophenolic acid can cause birth defects and should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
  • Regular monitoring: Your doctor will likely want to monitor your blood levels regularly to ensure the medication is working properly and to check for any potential side effects.
  • Other medications: Mycophenolic acid is often used in combination with other immunosuppressants, such as tacrolimus or cyclosporine. Make sure your doctor knows about all medications you’re taking[1].
Aspect Details
Primary Uses Prevention of organ rejection in transplant patients, particularly kidney transplants; Treatment of autoimmune conditions like lupus nephritis
Mechanism of Action Inhibits inosine monophosphate dehydrogenase (IMPDH), suppressing T and B lymphocyte proliferation
Common Dosages 720 mg to 1440 mg per day, often divided into two doses
Formulations Enteric-coated tablets (e.g., Myfortic), standard tablets
Combination Therapy Often used with other immunosuppressants like tacrolimus, cyclosporine, and corticosteroids
Key Outcomes Measured Incidence of acute rejection, renal function, proteinuria, adverse events
Potential Side Effects Gastrointestinal issues, increased risk of infections, blood disorders
Monitoring Regular blood tests, assessment of kidney function, screening for infections

FAQ

  • What is mycophenolic acid used for? Mycophenolic acid is primarily used as an immunosuppressant drug to prevent organ rejection in transplant patients, particularly for kidney transplants. It is also being studied for use in treating autoimmune conditions like lupus nephritis and uveitis.
  • How does mycophenolic acid work? Mycophenolic acid works by inhibiting an enzyme called inosine monophosphate dehydrogenase (IMPDH). This blocks the production of guanosine nucleotides, which are needed for DNA synthesis in T and B lymphocytes. By doing this, it suppresses the proliferation of these immune cells.
  • What are some potential side effects of mycophenolic acid? Common side effects can include gastrointestinal issues like diarrhea, nausea, and abdominal pain. It may also increase the risk of infections. Some patients may experience blood disorders like anemia or low white blood cell counts. Regular monitoring by a doctor is important.
  • How is mycophenolic acid administered? Mycophenolic acid is typically given orally in tablet form. The dosage and frequency can vary depending on the specific condition being treated and other factors. Common dosages in trials ranged from 720 mg to 1440 mg per day, often split into two daily doses.
  • Is mycophenolic acid used alone or with other medications? Mycophenolic acid is usually used in combination with other immunosuppressant drugs as part of a treatment regimen. In transplant patients, it's often combined with drugs like tacrolimus, cyclosporine, and corticosteroids. The specific combination depends on the patient's condition and treatment protocol.

Ongoing Clinical Trials on Mycophenolic Acid

  • Study of immunosuppression reduction in kidney transplant patients with septic shock or respiratory failure receiving drug combination therapy in intensive care

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Tacrolimus and Sirolimus for Kidney Transplant Patients at High Risk of Cytomegalovirus Infection

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Romania Spain

  • Study on the Safety of Eight Treg and Drug Combination for Patients with Chronic Kidney Failure Undergoing Transplant from a Living Donor

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark France Germany Hungary +7

  • Study on Optimal Dose of Rabbit Anti-Human T-Lymphocyte Immunoglobulin and Mycophenolic Acid for Kidney Transplant Patients with Low Immunological Risk

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland Spain

  • Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Cyprus Czechia Denmark +13

  • Study on Reducing Tacrolimus in Kidney Transplant Patients with Low Immunological Risk Using Tacrolimus, Mycophenolic Acid, and Prednisone

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Norway Spain

Glossary

  • Acute rejection: A sudden attack by the immune system on a transplanted organ, which can lead to organ failure if not treated promptly. It is diagnosed through a biopsy of the transplanted organ.
  • Banff criteria: A standardized system used to classify and grade rejection in transplanted kidneys based on biopsy findings. It helps doctors determine the severity of rejection and guide treatment decisions.
  • Cytomegalovirus (CMV): A common virus that can cause serious complications in transplant patients due to their weakened immune systems. Preventing and managing CMV infection is an important part of post-transplant care.
  • Enteric-coated: A type of coating on pills that prevents them from dissolving in the stomach, instead allowing them to dissolve in the small intestine. This can help reduce stomach irritation from certain medications.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood. It's an important indicator of kidney function in transplant patients and those with kidney disease.
  • Immunosuppression: The deliberate suppression of the immune system, usually through medications, to prevent rejection of transplanted organs or to treat autoimmune diseases.
  • Lupus nephritis: A type of kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease. It can lead to kidney damage if not properly treated.
  • Mycophenolate mofetil: The precursor drug to mycophenolic acid. It is converted to mycophenolic acid in the body and is used for similar purposes.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. Understanding a drug's pharmacokinetics helps determine proper dosing and administration.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney damage or disease. Monitoring proteinuria is important in assessing kidney function in transplant patients and those with kidney disorders.

References

  1. https://clinicaltrials.gov/study/NCT00374803
  2. https://clinicaltrials.gov/study/NCT00585468
  3. https://clinicaltrials.gov/study/NCT00676221
  4. https://clinicaltrials.gov/study/NCT00574197
  5. https://clinicaltrials.gov/study/NCT04645589
  6. https://clinicaltrials.gov/study/NCT01261169
  7. https://clinicaltrials.gov/study/NCT02328963